RenovoRx (RNXT) Q1 2025 earnings summary

Executive summary

• Achieved first full quarter of commercial revenue for RenovoCath, generating approximately $200,000 in Q1 2025, exceeding internal expectations and marking a key milestone following the initial launch in late 2024.

• The TAMP therapy platform aims to improve cancer treatment by delivering chemotherapy directly to tumors, with promising interim clinical results and strong physician support.

• Cash and cash equivalents stood at $14.6 million as of March 31, 2025, expected to fund commercialization and completion of the Phase III TIGER-PaC clinical trial.

• Management and Board members purchased approximately 143,000 shares in open market transactions, signaling confidence.

• Ongoing pivotal Phase III TIGER-PaC trial for locally advanced pancreatic cancer continues, with 91 of 114 patients randomized and a second interim analysis underway.

Financial highlights

• Q1 2025 revenue reached approximately $200,000, up from $0 in Q1 2024, reflecting strong organic demand and marking the first full quarter of product sales.

• Research and development expenses were $1.7 million, up from $1.3 million year-over-year, mainly due to increased compensation, manufacturing, and scale-up costs.

• Selling, general, and administrative expenses rose to $1.6 million from $1.2 million in the prior year, driven by higher personnel and commercialization costs.

• Net loss widened to $2.4 million for Q1 2025, compared to $1.1 million in Q1 2024, reflecting higher operating expenses and a decrease in warrant liability value.

• Gross margin for Q1 2025 was approximately 52%, with gross profit of $103,000.

Outlook and guidance

• Expects sequential quarter-over-quarter revenue growth for the remainder of 2025 as commercial adoption expands.

• Full enrollment for the TIGER-PaC trial is expected in 2025, with a second interim data analysis scheduled for Q3.

• Cash position anticipated to fund operations through key milestones, but additional capital may be needed for long-term growth and regulatory milestones.

• Expansion into international markets is under consideration, with a focus on the U.S. market in the near term.

• Anticipates increased expenses as commercialization and clinical activities expand.